MOYOM Achieves EU MDR Certification in Regenerative Aesthetics with APHRANEL® and Expert Collaboration

MOYOM's Breakthrough in Regenerative Aesthetics

On July 31, 2026, MOYOM, the innovative biotechnology company renowned for its advanced product APHRANEL®, celebrated two monumental achievements in its European operational strategy. Firstly, they attained the prestigious certification under the European Medical Device Regulation (EU MDR) for APHRANEL®, awarded by BSI UK, a leading Notified Body recognized worldwide. Secondly, they forged a strategic scientific partnership with Expert2Expert (E2E), an esteemed organization guided by the prominent aesthetic surgeon, Dr. Patrick Trévidic.

Significance of EU MDR Certification

Obtaining the EU MDR certification signifies that APHRANEL® complies with the stringent quality, safety, and performance standards mandated by the European Union, thus granting MOYOM vital access to the European market. However, for MOYOM, this certification is not merely a milestone; it's the initiation of a new, broader scientific journey, emphasizing the importance of gaining the trust of healthcare professionals. As Guangming Lin, CEO and Founder of MOYOM, stated, "Obtaining market access is only the first challenge. Earning physicians' confidence is the one that matters most."

Building a Scientific Foundation

In the wake of this certification, MOYOM has embarked on a collaboration with Dr. Patrick Trévidic and his team at Expert2Expert. With over 20 years of expertise in aesthetic medicine, E2E aims to establish a robust scientific platform aimed at enhancing the field of regenerative aesthetics throughout Europe. This partnership's focal point will be the integration of anatomical research, sophisticated cadaver studies, evidence generation through clinical trials, and education for physicians.

Dr. Trévidic brings a wealth of knowledge with over 35 years in aesthetic surgery, alongside numerous peer-reviewed publications and notable textbooks, significantly strengthening the collaboration. This partnership embodies a shared dedication to evidence-based innovation while maintaining scientific autonomy. Dr. Trévidic expressed his sentiments regarding the collaboration, stating, "Scientific progress is never achieved by one individual or one company alone. It is built through collaboration, curiosity, and the continuous pursuit of stronger evidence."

A Vision for the Future

The partnership will develop extensive scientific programs targeting advanced anatomical studies and fostering international clinical research. This initiative is designed to elevate the medical credibility of APHRANEL® across Europe, fostering confidence among healthcare providers and ultimately leading to enhanced patient outcomes.

Patrice Delobel, PhD, European Medical and Marketing Director at MOYOM, conveyed their ambition: "When I decided to join MOYOM, my aim was to build a scientific platform that physicians could depend on for years to come. This collaboration with Expert2Expert marks a significant step towards that vision."

MOYOM's Philosophical Underpinnings

The foundation of MOYOM's long-term strategy can be encapsulated in its Care Lifetime Value philosophy, prioritizing three core tenets: care, lifetime, and value.

- Care reflects the company's dedication to supporting patients through rigorous scientific practices.
- Lifetime emphasizes the cultivation of enduring physician confidence via continual education and collaboration.
- Value speaks to the meaningful impacts made across the entire healthcare ecosystem, benefiting physicians, patients, and scientific communities alike.

In conclusion, with the EU MDR certification and collaboration with Expert2Expert, MOYOM is poised to lead the regenerative aesthetics field, pushing forward scientific research and innovative medical education while firmly focusing on evidence generation to fulfill their mission of improving patient lives through advanced aesthetic solutions. The journey that began in the laboratory is set to transform clinical practices, build trust, and ultimately enhance the quality of life for patients, demonstrating that science and trust together cultivate a brighter future in regenerative aesthetics.